Dr. Roger Mills is Addex's Chief Medical Officer and a Director. He brings more than 30 years of biopharmaceutical industry experience at both large global pharmaceutical companies and smaller biotechnology companies, including Acadia Pharmaceuticals, Pfizer, Gilead Sciences, Abbott Laboratories and The Wellcome Foundation. His track record includes managing drug development programs, INDs and NDAs as well as post-marketing and OTC products. Most recently he spent nine years at Acadia Pharmaceuticals as Executive Vice President, Development and Chief Medical Officer, where he oversaw the largest ever international Phase 3 program in Parkinson's Disease Psychosis and led the NDA submission to the FDA for NUPLAZID. He is an Honorary Professor at the University of Exeter, a Fellow of the Faculty of Pharmaceutical Medicine and a member of the board of Enterin Inc. He received his medical degree from Imperial College, Charing Cross Hospital Medical School, London. During 2025 he was remunerated only as a Board member, as he spent most of his time acting as a director rather than as Chief Medical Officer.